Opportunity Information: Apply for RFA HL 15 013
Apply for RFA HL 15 013
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Cardiovascular Development Consortium (UM1)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.837 Cardiovascular Diseases Research.
- This funding opportunity was created on Jul 8, 2014 and posted on Jul 8, 2014.
- Applicants must submit their applications by Oct 15, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,400,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) City or township governments Public and State controlled institutions of higher education State governments Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Special district governments County governments Small businesses For profit organizations other than small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Foreign Institutions Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Cardiovascular Development Consortium (CvDC) (UM1) funding opportunity, issued by the National Institutes of Health under RFA-HL-15-013, supported a continuation of an existing multi-site research consortium focused on cardiovascular development and congenital heart disease (CHD). The main goal was to fund a small number of Research Centers that could work together to push forward the science of how the heart and vascular system form, with an emphasis on mapping and understanding the biological networks that guide normal development and, when disrupted, lead to human CHD. A central theme of the announcement is that progress in this area requires coordinated, team-based science across multiple institutions rather than isolated projects, because the key questions span diverse model systems, data types, and clinical translation needs.
The CvDC was designed as a collaborative network of Research Centers, each bringing distinct but complementary expertise to address major scientific challenges in cardiovascular development. Rather than functioning as separate, independent awards, the Centers were expected to coordinate research directions, share insights and resources, and collectively tackle problems that benefit from cross-center integration. The consortium structure was intended to align different strengths, such as developmental biology, genetics, genomics, functional studies, and mechanistic work, so that discoveries about developmental pathways could be connected more directly to the causes and mechanisms of CHD.
A major translational feature of this opportunity was its explicit linkage to two other NIH-supported efforts: the Pediatric Cardiac Genomics Consortium (PCGC) and the Pediatric Heart Network (PHN). Through planned interactions with PCGC and PHN, CvDC investigators were meant to connect basic developmental biology and mechanistic research to human genomic findings and, where appropriate, clinical research infrastructure. Together, CvDC, PCGC, and PHN formed the Bench to Bassinet (B2B) Program, highlighting a pipeline from fundamental discovery (bench) to pediatric and clinical relevance (bassinet). The announcement also emphasized that institutions not currently part of the CvDC were encouraged to apply, particularly if they could bring new research directions and capabilities that would strengthen the consortium.
From an administrative and funding standpoint, this was a discretionary grant opportunity using a cooperative agreement mechanism (UM1). A cooperative agreement signals substantial NIH programmatic involvement compared with a standard investigator-initiated grant, reflecting that the funded Centers would be expected to operate as parts of a managed consortium with shared goals, coordination, and collaborative expectations. The funding activity category was Health, with the CFDA listing 93.837 (Cardiovascular Diseases Research). The FOA anticipated making about 4 awards, with an estimated total funding level of $3.4 million and an award ceiling of $500,000. Cost sharing or matching was not required.
Eligibility was broad and included many U.S.-based organizational types, spanning public and private institutions of higher education, nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) nonprofits), small businesses, for-profit organizations (with distinctions between small and other-than-small), independent school districts, and various levels of government entities (city/township, county, state, special district, and certain housing authorities). It also explicitly included a range of mission-driven or designated institution types such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISI institutions, along with faith-based and community-based organizations, and eligible federal agencies. Foreign institutions and other non-U.S. entities were not eligible to apply, and non-U.S. components of U.S. organizations were not eligible; however, foreign components as defined by NIH policy were allowed, which typically means a U.S. applicant could include certain foreign collaborations under NIH rules when scientifically justified.
Key dates show this was a time-limited competition: it was posted on July 8, 2014, with an original and current closing date of October 15, 2014, and it was archived on November 15, 2014. The full announcement was available through the NIH Grants Guide at the provided link. For access or technical issues, the listing directed applicants to the NIH Office of Extramural Research (OER) webmaster contact.
Frequently Asked Questions (FAQs): Cardiovascular Development Consortium (CvDC) (UM1) - RFA-HL-15-013
What is this funding opportunity?
This opportunity is the Cardiovascular Development Consortium (CvDC) (UM1) funding opportunity issued by the National Institutes of Health (NIH) under RFA-HL-15-013. It supported a continuation of an existing multi-site research consortium focused on cardiovascular development and congenital heart disease (CHD).
What was the main purpose of the CvDC program?
The primary goal was to fund a small number of Research Centers that could work together to advance the science of how the heart and vascular system form. A key emphasis was on mapping and understanding the biological networks that guide normal development and, when disrupted, contribute to human CHD.
What scientific focus areas were emphasized?
The announcement emphasized coordinated efforts to understand developmental pathways and biological networks underlying cardiovascular development, and how disruptions in those processes can lead to congenital heart disease. The consortium structure was intended to integrate multiple approaches and data types rather than relying on isolated projects.
Why was a consortium approach required instead of separate individual projects?
A central theme was that progress in cardiovascular development and CHD requires coordinated, team-based science across multiple institutions. The key questions span diverse model systems, data types, and clinical translation needs, making cross-center integration important.
How was the CvDC structured?
The CvDC was designed as a collaborative network of Research Centers. Each Center was expected to bring distinct but complementary expertise and to coordinate with other Centers by sharing insights and resources and aligning research directions to address major scientific challenges collectively.
Were the Research Centers intended to operate independently?
No. The Centers were not expected to function as separate, independent awards. They were expected to operate as parts of an integrated consortium with shared goals, coordination, and collaboration across sites.
What types of expertise were expected across the consortium?
The consortium was intended to align different strengths such as developmental biology, genetics, genomics, functional studies, and mechanistic research, so that discoveries about developmental pathways could be connected more directly to the causes and mechanisms of CHD.
How did this opportunity connect to translation and clinical relevance?
A major translational feature was the explicit linkage to two other NIH-supported efforts: the Pediatric Cardiac Genomics Consortium (PCGC) and the Pediatric Heart Network (PHN). Planned interactions were meant to connect basic developmental biology and mechanistic research to human genomic findings and, where appropriate, clinical research infrastructure.
What is the Bench to Bassinet (B2B) Program in this context?
CvDC, PCGC, and PHN together formed the Bench to Bassinet (B2B) Program. The concept highlighted a pipeline from fundamental discovery (bench) to pediatric and clinical relevance (bassinet).
Could institutions not already in the CvDC apply?
Yes. The announcement explicitly encouraged institutions not currently part of the CvDC to apply, particularly if they could contribute new research directions and capabilities that would strengthen the consortium.
What funding mechanism was used?
This was a discretionary grant opportunity using a cooperative agreement mechanism (UM1).
What does the UM1 cooperative agreement mechanism imply?
A cooperative agreement indicates substantial NIH programmatic involvement compared with a standard investigator-initiated grant. In this opportunity, it reflected that funded Centers would be expected to operate as parts of a managed consortium with shared goals and coordinated activities.
What is the activity category and CFDA number?
The funding activity category was Health. The CFDA listing was 93.837 (Cardiovascular Diseases Research).
How many awards were anticipated?
The FOA anticipated making about 4 awards.
What was the estimated total funding level?
The estimated total funding level was $3.4 million.
What was the award ceiling?
The award ceiling was $500,000.
Was cost sharing or matching required?
No. Cost sharing or matching was not required.
Who was eligible to apply?
Eligibility was broad and included many U.S.-based organizational types, including public and private institutions of higher education, nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) nonprofits), small businesses, for-profit organizations (including small and other-than-small), independent school districts, and various levels of government entities (city/township, county, state, special district, and certain housing authorities). It also included faith-based and community-based organizations and eligible federal agencies.
Were designated institution types specifically included?
Yes. The eligibility language explicitly included institution types such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISI institutions.
Were foreign institutions eligible to apply?
No. Foreign institutions and other non-U.S. entities were not eligible to apply.
Could a U.S. organization include a non-U.S. component?
Non-U.S. components of U.S. organizations were not eligible. However, foreign components as defined by NIH policy were allowed, meaning certain foreign collaborations could be included under NIH rules when scientifically justified.
When was the opportunity posted and when did it close?
It was posted on July 8, 2014. The original and current closing date was October 15, 2014.
Is this opportunity still open?
No. The opportunity was archived on November 15, 2014, indicating it was a time-limited competition that is no longer active.
Where could applicants find the full announcement?
The full announcement was available through the NIH Grants Guide at the link provided in the listing.
Who should be contacted for access or technical issues related to the announcement listing?
For access or technical issues, the listing directed applicants to contact the NIH Office of Extramural Research (OER) webmaster.
Browse more opportunities from the same category: Health
Next opportunity: ROSES 2014 K2 Guest Observer Cycle 1
Previous opportunity: Pediatric Cardiac Genomics Consortium (UM1)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 15 013
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 15 013) also looked into and applied for these:
| Funding Opportunity |
|---|
| Affordable Care Act New Access Point Grants Apply for HRSA 15 016 Funding Number: HRSA 15 016 Agency: Health Resources and Services Administration Category: Health Funding Amount: $650,000 |
| PPHF 2014 Immunization Improving Immunization Rates and Enhancing Disease Prevention through Partnerships with Providers and National Organizations that focus on Public Health financed solely by 2014 Prevention and Public Health Funds Apply for CDC RFA IP14 1405PPHF14 Funding Number: CDC RFA IP14 1405PPHF14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
| Cote dIvoire Resources Towards Elimination of Child Vulnerability (REVE Cote dIvoire) Apply for RFA 624 14 000014 Funding Number: RFA 624 14 000014 Agency: Ghana USAID Accra Category: Health Funding Amount: $21,940,000 |
| The Electronic Medical Records and Genomics (eMERGE) Network, Phase III Study Investigators (U01) Apply for RFA HG 14 025 Funding Number: RFA HG 14 025 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Revision Applications for Research Using Aged Animal Models to Study Chronic Disorders of Heart, Lung, Blood, and Sleep (R01) Apply for RFA HL 15 005 Funding Number: RFA HL 15 005 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| Implementation of Strategic Plans for Billing for Immunization Services in Health Department Clinics Apply for CDC RFA IP14 1411 Funding Number: CDC RFA IP14 1411 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| Blood Pressure Measurement Technologies for Low Resource Settings in the US and India (U01) Apply for RFA EB 14 002 Funding Number: RFA EB 14 002 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Service Area Competition Additional Area (SAC AA) Baltimore, MD Apply for HRSA 15 118 Funding Number: HRSA 15 118 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Aging and Neuromuscular Junctions (R01) Apply for RFA AG 15 008 Funding Number: RFA AG 15 008 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Pilot Centers for Precision Disease Modeling (U54) Apply for PAR 14 280 Funding Number: PAR 14 280 Agency: National Institutes of Health Category: Health Funding Amount: $4,000,000 |
| Career Transition Award for NINDS Intramural Clinician Scientists (K22) Apply for PAR 14 282 Funding Number: PAR 14 282 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Zambia Family Apply for RFA 611 14 000005 Funding Number: RFA 611 14 000005 Agency: Zambia USAID Lusaka Category: Health Funding Amount: $15,000,000 |
| Summer Research Training in Aging for Medical Students (T35) Apply for RFA AG 15 009 Funding Number: RFA AG 15 009 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| The Electronic Medical Records and Genomics (eMERGE) Network, Phase III Coordinating Center (U01) Apply for RFA HG 14 026 Funding Number: RFA HG 14 026 Agency: National Institutes of Health Category: Health Funding Amount: $1,100,000 |
| The Electronic Medical Records and Genomics (eMERGE) Network, Phase III Central Sequencing and Genotyping Facility (U01) Apply for RFA HG 14 027 Funding Number: RFA HG 14 027 Agency: National Institutes of Health Category: Health Funding Amount: $4,000,000 |
| USAID/Uganda Comprehensive HIV/AIDS and Health Services at the Workplace Activity Apply for RFA 617 14 000007 Funding Number: RFA 617 14 000007 Agency: Uganda USAID Kampala Category: Health Funding Amount: $15,000,000 |
| NINDS CREATE Bio Discovery Track Optimization in Preparation for Development of Biotechnology Products and Biologics (U01) Apply for PAR 14 286 Funding Number: PAR 14 286 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS CREATE Bio Discovery Track Optimization in Preparation for Development of Biotechnology Products and Biologics (U44) Apply for PAR 14 287 Funding Number: PAR 14 287 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NINDS CREATE Bio Development Track Preclinical and Early phase Clinical Development for Biotechnology Products and Biologics (U44) Apply for PAR 14 289 Funding Number: PAR 14 289 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Comprehensive Community HIV Prevention Program for Key and Vulnerable Populations (CP2) Apply for SOL 621 14 000015 Funding Number: SOL 621 14 000015 Agency: Tanzania USAID Dar es Salaam Category: Health Funding Amount: $73,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 15 013", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.